Bijsluiter: informatie voor de patiënt

Bosentan Sandoz® 62,5 mg, filmomhulde tabletten
Bosentan Sandoz® 125 mg, filmomhulde tabletten

bosentan

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, please ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What [Nationally completed name] is and what it is used for

[Nationally completed name] tablets contain bosentan, which blocks a naturally occurring hormone called endothelin-1 (ET-1), which causes blood vessels to narrow. [Nationally completed name] therefore causes blood vessels to expand and belongs to the class of medicines called “endothelin receptor antagonists”.

[Nationally completed name] is used to treat:
- **Pulmonary arterial hypertension** (PAH): PAH is a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. [Nationally completed name] widens the pulmonary arteries, making it easier for the heart to pump blood through them. This lowers the blood pressure and relieves the symptoms.

  [Nationally completed name] is used to treat patients with class III pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity) and symptoms. The ‘class’ reflects the seriousness of the disease: ‘class III’ involves marked limitation of physical activity. Some improvements have also been shown in patients with class II PAH. ‘Class II’ involves slight limitation of physical activity. The PAH for which [Nationally completed name] is indicated can be:
  - primary (with no identified cause or familial);
  - caused by scleroderma (also called systemic sclerosis, a disease where there is abnormal growth of the connective tissue that supports the skin and other organs);
  - caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing abnormal flow of blood through the heart and lungs.

- **Digital ulcers:** (sores on the fingers and toes) in adult patients with a condition called scleroderma. [Nationally completed name] reduces the number of new finger and toe ulcers that appear.

2. What you need to know before you take [Nationally completed name]

Do not take [Nationally completed name]

- **if you are allergic to bosentan** or any of the other ingredients of this medicine (listed in section 6)
- **if you have liver problems** (ask your doctor)
- **if you are pregnant, or could get pregnant** because you are not using reliable contraceptive methods. Please read the information under "Contraceptives" and "Other medicines and [Nationally completed name]"
- **if you are taking cyclosporine A** (a medicine used after a transplant or to treat psoriasis)

If any of these apply to you, tell your doctor.

Warnings and precautions
Talk to your doctor or pharmacist before taking [Nationally completed name].

Tests your doctor will do before treatment
- a blood test to check your liver function
- a blood test to check for anaemia (low haemoglobin)
- a pregnancy test if you are a woman of childbearing potential

Some patients taking [Nationally completed name] have been found to have abnormal liver function tests and anaemia (low haemoglobin).

Tests your doctor will do during treatment
During treatment with [Nationally completed name], your doctor will arrange for regular blood tests to check for changes in your liver function and haemoglobin level.

For all these tests please refer also to the Patient Alert Card (inside your pack of [Nationally completed name] tablets). It is important that you have these regular blood tests as long as you are taking [Nationally completed name]. We suggest you write the date of your most recent test and also of your next test (ask your doctor for the date) on the Patient Alert Card, to help you remember when your next test is due.

Blood tests for liver function
These will be done every month for the duration of treatment with [Nationally completed name]. After an increase in dose an additional test will be done after 2 weeks.

Blood tests for anaemia
These will be done every month for the first 4 months of treatment, then every 3 months after that, as patients taking [Nationally completed name] may get anaemia.

If these results are abnormal, your doctor may decide to reduce your dose or stop treatment with [Nationally completed name] and to perform further tests to investigate the cause.

Children and adolescents

[Nationally completed name] is not recommended in paediatric patients with systemic sclerosis and ongoing digital ulcer disease. [Nationally completed name] should also not be used in children with a body weight below 31 kg with pulmonary arterial hypertension. Please see also section 3. "How to take [Nationally completed name]".

Other medicines and [Nationally completed name]
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. It is especially important to tell your doctor if you are taking:

- cyclosporine A (a medicine used after transplants and to treat psoriasis), which must not be used together with [Nationally completed name]
- sirolimus or tacrolimus, which are medicines used after transplants, as these are not recommended to be used together with [Nationally completed name]
- glibenclamide (a diabetes medicine), rifampicin (a tuberculosis medicine), fluconazole (a medicine against fungal infections), ketoconazole (a medicine used to treat Cushing´s syndrome) or nevirapine (an HIV medicine), as these medicines are not recommended to be used together with [Nationally completed name]
- other medicines for the treatment of HIV infection, which may require special monitoring if used together with [Nationally completed name]
- hormonal contraceptives, which are not effective as the sole method of contraception when you take [Nationally completed name]. Inside your pack of [Nationally completed name] tablets you will find a Patient Alert Card which you should read carefully. Your doctor and/or gynaecologist will establish the contraception which is appropriate for you
- other medicines for the treatment of pulmonary hypertension: sildenafil and tadalafil
- warfarin (an anticoagulant agent)
- simvastatin (used to treat hypercholesterolemia).

Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Women of childbearing age
Do NOT take [Nationally completed name] if you are pregnant or planning to become pregnant.

Pregnancy tests
[Nationally completed name] may harm unborn babies conceived before starting or during treatment. If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking [Nationally completed name], and regularly while you are taking [Nationally completed name].

Contraceptives
If it is possible that you could become pregnant, use a reliable form of birth control (contraception) while you are taking [Nationally completed name]. Your doctor or gynaecologist will advise you about reliable contraceptive methods while taking [Nationally completed name]. Because [Nationally completed name] may make hormonal contraception (e.g., oral, injection, implant, or skin patches) ineffective, this method on its own is not reliable. Therefore, if you use hormonal contraceptives you must also use a barrier method (e.g., female condom, diaphragm, contraceptive sponge, or your partner must also use a condom). Inside your pack of [Nationally completed name] tablets you will find a Patient Alert Card. You should complete this card and take it to your doctor at your next visit so that your doctor or gynaecologist can assess whether you need additional or alternative reliable contraceptive methods. Monthly pregnancy tests are recommended while you are taking [Nationally completed name] and are of childbearing age.

Tell your doctor immediately if you become pregnant while you are taking [Nationally completed name], or plan to become pregnant in the near future.

Breast-feeding
[Nationally completed name] passes into your breast milk. You are advised to stop breast-feeding if [Nationally completed name] is prescribed for you, because it is not known if [Nationally completed name] in breast milk can harm your baby. Talk to your doctor about this.

Fertility
If you are a man taking [Nationally completed name], it is possible that this medicine may lower your sperm count. It cannot be excluded that this may affect your ability to father a child. Talk to your doctor if you have any questions or concerns about this.

Driving and using machines
[Nationally completed name] has no or negligible influence on the ability to drive and use machines. However, [Nationally completed name] can induce hypotension (decrease of your blood pressure) which can make you feel dizzy, affect your vision and affect your ability to drive and use machines. Therefore, if you feel dizzy or that your vision is blurred while taking [Nationally completed name], do not drive or operate any tools or machines.

[Nationally completed name] contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.

3. How to take [Nationally completed name]

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Treatment with [Nationally completed name] should only be started and monitored by a doctor who has experience in the treatment of PAH or systemic sclerosis.

Recommended dose

Adult
The treatment in adults is usually started for the first 4 weeks with 62.5 mg twice daily (morning and evening), from then your doctor will usually advise you to take a 125 mg tablet twice daily, depending on how you react to [Nationally completed name].

Children and adolescents
The dose recommendation in children is only for PAH. For children aged 1 year and older, treatment with [Nationally completed name] is usually started with 2 mg per kg bodyweight twice daily (morning and evening). However, some doses of bosentan are not possible in children with a body weight below 31 kg. For such patients a bosentan tablet with lower strength is needed. Your doctor will advise you on your dosing.
Please note that bosentan is also available as a dispersible 32 mg tablet formulation, which may make correct dosing easier for children and patients with low body weight or difficulties to swallow film-coated tablets.
If you have the impression that the effect of [Nationally completed name] is too strong or too weak, talk to your doctor in order to find out whether your dose needs to be changed.

How to take [Nationally completed name]

Tablets should be taken (morning and evening), swallowed with water. The tablets can be taken with or without food.

If you take more [Nationally completed name] than you should
If you take more tablets than you have been told to take, contact your doctor immediately.

If you forget to take [Nationally completed name]
If you forget to take [Nationally completed name], take a dose as soon as you remember, then continue to take your tablets at the usual times. Do not take a double dose to make up for a forgotten tablet.

If you stop taking [Nationally completed name]
Suddenly stopping your treatment with [Nationally completed name] may lead to your symptoms getting worse. Do not stop taking [Nationally completed name] unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The most serious side effects with [Nationally completed name] are
- Abnormal liver function which may affect more than 1 in 10 people
- Anaemia (low blood value) which may affect up to 1 in 10 people. Anaemia may occasionally require blood transfusion.

Your liver and blood values will be monitored during treatment with [Nationally completed name] (see section 2). It is important that you have these tests as ordered by your doctor.

Signs that your liver may not be working properly include:
- nausea (urge to vomit)
- vomiting
- fever (high temperature)
- pain in your stomach (abdomen)
- jaundice (yellowing of your skin or the whites of your eyes)
- dark-coloured urine
- itching of your skin
- lethargy or fatigue (unusual tiredness or exhaustion)
- flu-like syndrome (joint and muscle pain with fever)

If you notice any of these signs **tell your doctor immediately**.

Other side effects:

Very common (may affect **more than one in 10** people):
- Headache
- Oedema (swelling of the legs and ankles or other signs of fluid retention)

Common (may affect **up to one in 10** people):
- Flushed appearance or redness of skin
- Hypersensitivity reactions (including skin inflammation, itching and rash)
- Gastrooesophageal reflux disease (acid reflux)
- Diarrhoea

- Syncope (fainting)
- Palpitations (fast or irregular heartbeats)
- Low blood pressure
- Nasal congestion

Uncommon (may affect **up to one in 100** people):
- Thrombocytopenia (low number of blood platelets)
- Neutropenia/leukopenia (low number of white blood cells)
- Elevated liver function tests with hepatitis (inflammation of the liver) including possible exacerbation of underlying hepatitis and/or jaundice (yellowing of the skin or the whites of the eyes)

Rare (may affect **up to one in 1,000** people):
- Anaphylaxis (general allergic reaction), angioedema (swelling, most commonly around the eyes, lips, tongue or throat)
- Cirrhosis (scarring) of the liver, liver failure (serious disturbance of liver function)

Blurred vision has also been reported at not known frequency (frequency cannot be estimated from the available data).

Side effects in children and adolescents
The side effects that have been reported in children treated with [Nationally completed name] are the same as those in adults.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [Nationally completed name]

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after "EXP". The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What [Nationally completed name] contains

The active substance is bosentan (as monohydrate).
Each tablet contains 62.5 mg of bosentan (corresponding to 64.541 mg bosentan monohydrate).

Each tablet contains 125 mg of bosentan (corresponding to 129.082 mg bosentan monohydrate).

The other ingredients in the tablet core are maize starch; pregelatinised maize starch; sodium starch glycolate Type A; povidone K 30; poloxamer 188; silica, colloidal anhydrous; glycerol dibehenate and magnesium stearate.

The film-coat contains Opadry Orange 21K23007 (containing hypromellose, titanium dioxide (E 171), ethylcellulose, triacetin (E 1518), talc (E 553b), yellow iron oxide (E 172), red iron oxide (E 172), black iron oxide (E 172).

What [Nationally completed name] looks like and contents of the pack

62.5 mg film-coated tablets:
are light orange, round, biconvex film-coated tablets of 6 mm.

125 mg film-coated tablets:
are light orange, oval, biconvex film-coated tablets of 11 x 5 mm.

The film-coated tablets are packed in PVC/PVDC/aluminium-blisters and inserted in a carton.

Pack sizes:
14, 56 or 112 film-coated tablets

Not all pack sizes may be marketed.

Houder van de vergunning voor het in de handel brengen en fabrikant

Vergunninghouder:
Sandoz B.V., Hospitaaldreef 29, 1315 RC Almere, Nederland

Fabrikant:
Salutas Pharma GmbH
Otto-von Guericke-Allee 1
39179 Barleben
Germany

Lek Pharmaceuticals d.d.
Verovškova ulica 57,
1526 Ljubljana
Slovenië

In het register ingeschreven onder:

RVG 117029, Bosentan Sandoz 62,5 mg, filmomhulde tabletten
RVG 117030, Bosentan Sandoz 125 mg, filmomhulde tabletten

Dit geneesmiddel is geregistreerd in lidstaten van de Europese Economische Ruimte onder de volgende namen:

Nederland
Bosentan Sandoz 62,5 mg, filmomhulde tabletten
Bosentan Sandoz 125 mg, filmomhulde tabletten

Duitsland

Bosentan - 1 A Pharma 62,5 mg Filmtabletten
Bosentan - 1 A Pharma 125 mg Filmtabletten

Deze bijsluiter is voor het laatst goedgekeurd in januari 2025.